仁和药业
(000650)
| 流通市值：68.30亿 | | | 总市值：71.82亿 |
| 流通股本：13.31亿 | | | 总股本：14.00亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,791,652,026.3 | 2,090,941,027.03 | 1,129,224,010.41 | 3,536,422,014.45 |
| 营业收入 | 2,791,652,026.3 | 2,090,941,027.03 | 1,129,224,010.41 | 3,536,422,014.45 |
| 二、营业总成本 | 2,257,169,543.37 | 1,670,769,053.24 | 892,993,180.85 | 2,913,953,460.09 |
| 营业成本 | 1,773,157,666.76 | 1,338,981,178.91 | 714,756,977.68 | 2,229,233,513.06 |
| 税金及附加 | 30,637,792.82 | 21,412,258.92 | 10,127,444.47 | 38,011,612.8 |
| 销售费用 | 218,103,246.66 | 145,730,279.42 | 74,791,943.95 | 345,393,966.88 |
| 管理费用 | 209,703,574.15 | 148,892,803.14 | 86,401,971.7 | 255,855,558.88 |
| 研发费用 | 25,115,069.78 | 15,228,347.8 | 7,452,851 | 45,065,951.51 |
| 财务费用 | 452,193.2 | 524,185.05 | -538,007.95 | 392,856.96 |
| 其中:利息费用 | 50,152.51 | 35,006.92 | 18,396.36 | 86,906.3 |
| 其中:利息收入 | 1,022,303.17 | 822,319.15 | 664,402.07 | 2,695,760.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 44,091,966.31 | 29,539,733.37 | -2,426,648.3 | 25,116,621.86 |
| 加:投资收益 | 20,631,671.47 | 15,330,658.7 | 5,498,491.4 | 83,430,024.12 |
| 资产处置收益 | -30,309.36 | -41,579.62 | 4,757.02 | 2,048,182.02 |
| 资产减值损失(新) | -190,743.77 | -169,209.19 | 661.3 | -129,175,268.45 |
| 信用减值损失(新) | -7,712,889.22 | -7,721,243.25 | 3,232.1 | -32,539,266.08 |
| 其他收益 | 9,904,136.85 | 6,907,324.38 | 3,721,066.57 | 93,863,226.2 |
| 四、营业利润 | 601,176,315.21 | 464,017,658.18 | 243,032,389.65 | 665,212,074.03 |
| 加:营业外收入 | 2,648,779.16 | 1,752,170.18 | 368,235.42 | 7,096,270.07 |
| 减:营业外支出 | 1,036,194.45 | 901,028.19 | 493,752.41 | 7,411,351.11 |
| 五、利润总额 | 602,788,899.92 | 464,868,800.17 | 242,906,872.66 | 664,896,992.99 |
| 减:所得税费用 | 145,712,225.63 | 109,486,235.68 | 64,676,882.55 | 177,240,243.54 |
| 六、净利润 | 457,076,674.29 | 355,382,564.49 | 178,229,990.11 | 487,656,749.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 457,076,674.29 | 355,382,564.49 | 178,229,990.11 | 487,656,749.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 372,171,309.37 | 291,949,140.28 | 140,374,777.74 | 393,208,100.62 |
| 少数股东损益 | 84,905,364.92 | 63,433,424.21 | 37,855,212.37 | 94,448,648.83 |
| 扣除非经常损益后的净利润 | 315,634,066.8 | 253,163,961.29 | 135,828,348.93 | 249,284,664.96 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.21 | 0.1 | 0.28 |
| (二)稀释每股收益 | 0.27 | 0.21 | 0.1 | 0.28 |
| 八、其他综合收益 | -45,889.74 | -35,537.68 | -20,777.29 | -5,987.04 |
| 归属于母公司股东的其他综合收益 | -45,889.74 | -35,537.68 | -20,777.29 | -5,987.04 |
| 九、综合收益总额 | 457,030,784.55 | 355,347,026.81 | 178,209,212.82 | 487,650,762.41 |
| 归属于母公司股东的综合收益总额 | 372,125,419.63 | 291,913,602.6 | 140,354,000.45 | 393,202,113.58 |
| 归属于少数股东的综合收益总额 | 84,905,364.92 | 63,433,424.21 | 37,855,212.37 | 94,448,648.83 |
| 公告日期 | 2026-10-27 | 2026-08-26 | 2026-04-28 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |